These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10717627)

  • 1. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer.
    Montenarh M; Harloziñska A; Bar JK; Kartarius S; Günther J; Sedlaczek P
    Int J Oncol; 1998 Sep; 13(3):605-10. PubMed ID: 9683801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer.
    Angelopoulou K; Diamandis EP
    Eur J Cancer; 1997 Jan; 33(1):115-21. PubMed ID: 9071910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.
    Zeimet AG; Widschwendter M; Knabbe C; Fuchs D; Herold M; Müller-Holzner E; Daxenbichler G; Offner FA; Dapunt O; Marth C
    J Clin Oncol; 1998 May; 16(5):1861-8. PubMed ID: 9586902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Gagetti O; Bevilacqua G; Genazzani AR
    Gynecol Oncol; 1999 Jan; 72(1):76-81. PubMed ID: 9889034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
    Vogl FD; Frey M; Kreienberg R; Runnebaum IB
    Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
    Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
    Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
    J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
    Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
    Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
    Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
    Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of ascites in epithelial ovarian cancer.
    Huang H; Li YJ; Lan CY; Huang QD; Feng YL; Huang YW; Liu JH
    Neoplasma; 2013; 60(5):546-52. PubMed ID: 23790174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
    Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
    Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.